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ABSTRACT  
Synthetic cannabinoid receptor agonists (SCRAs) are one of the largest groups of new 
psychoactive substances (NPS) monitored in Europe. SCRAs are known to typically exert 
higher cannabinoid activity than THC from cannabis, therefore entailing a greater health risk. 
Both Cumyl-PEGACLONE and 5F-Cumyl-PEGACLONE were not controlled by the national 
legislation upon their first detection in Germany in 2016 and 2017, respectively, and have been 
linked to several fatalities. In this study, the CB1 receptor activity of these compounds, together 
with two newly synthesized structural isomers (Cumyl-PEGACLONE ethylbenzyl isomer and 
n-propylphenyl isomer) was assessed using two different in vitro receptor-proximal bio-assays, 
monitoring the recruitment of either β-arrestin2 or a modified G protein (mini-Gαi) to the 
activated CB1 receptor. Both in terms of potency and relative efficacy, Cumyl-PEGACLONE 
and 5F-Cumyl-PEGACLONE were found to exert strong CB1 activation, with sub-nanomolar 
EC50 values, and efficacy values exceeding those of the reference agonist JWH-018 >3 fold 
(β-arrestin2 assay) or almost 2-fold (mini-Gαi assay). The ethylbenzyl and n-propylphenyl 
isomers showed a strongly reduced CB1 activity (EC50 values >100 nM; efficacy <40% relative 
to JWH-018), which is hypothesized to originate from steric hindrance in the ligand binding 
pocket. Therefore, their abuse potential seems less likely. None of the evaluated compounds 
showed significant biased agonism. In conclusion, the functional assays applied here allowed 
us to demonstrate that 5-fluorination of Cumyl-PEGACLONE is not linked to an intrinsically 
higher CB1 activation potential, and that the ethylbenzyl and n-propylphenyl isomers yield a 
strongly reduced CB1 activitation. 
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INTRODUCTION 
Synthetic cannabinoid receptor agonists (SCRAs) are a class of designer drugs that form one 
of the largest group of new psychoactive substances (NPS) monitored by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 1. Their synthesis for recreational 
purposes created legal alternatives to cannabis, mimicking the effect of the main psychotropic 
constituent ∆9-tetrahydrocannabinol (THC). However, in comparison to the partial agonist THC, 
SCRAs are often much more potent at the CB1 cannabinoid receptor, which is mainly 
responsible for the psychotropic effects. This more pronounced activity of SCRAs poses a 
higher risk for overdoses and serious adverse health effects, even though they may be 
marketed as ‘safe and legal’ alternatives to cannabis 2–4. Considering the plethora of health 
consequences, several national and/or international legislations have tried to include these 
NPS to prohibit their use/possession/trafficking, via the implementation of for example generic 
legislations that encompass all ‘variants’ of a certain core structure. However, although these 
legislations are able to ban clusters of NPS in advance, the regulation of these drugs is a 
never-ending challenge for national authorities. Novel compounds with either related or even 
completely divergent structures continue to be synthesized and sold on the internet, 
circumventing existing legislations, in line with the popular term ‘legal highs’ that is sometimes 
used to refer to these substances.  
The SCRA Cumyl-PEGACLONE (pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-
b]indol-1-one) was first identified in December 2016 in Germany within the framework of a 
profiling project for online monitoring of smokeable herbal mixtures containing SCRAs 5. The 
tricyclic γ-carboline-1-one core structure of this compound was rather unconventional and was 
not included in the German generic legislation (NpSG) of November 2016 to control 
‘cannabimimetics/synthetic cannabinoids’ by prohibiting all substances with core structures 
consisting of an indole, indazole or benzimidazole combined with specific side groups (Figure 
1). This circumvention of the NpSG legislation was postulated as the reason for the synthesis 
and sale in the first place. Cumyl-PEGACLONE initially appeared on the market in the form of 
herbal blends and e-liquids and became available as a pure ‘research chemical’ in July 2017 
6. Since then, several research groups have characterized this new compound, its 
metabolization, and, to a lesser extent, its cannabinoid activity. The psychoactive effects, most 
desired by (ab)users, but also several adverse effects, mainly stem from CB1 receptor 
activation. Angerer et al. reported a high binding affinity of Cumyl-PEGACLONE to the CB1 
receptor (Ki = 1.37 ± 0.24 nM) and scored the compound as a full agonist via a cAMP assay 5. 
We recently reported on the ultrahigh potency of this compound, using two distinct bio-assays, 
assessing the recruitment of either a modified G protein (mini-Gαi) or β-arrestin2 (β-arr2) to 
the activated CB1 receptor. With EC50 values of 0.07 nM (95% confidence interval (CI) 
0.02−0.22 nM) and 0.09 nM (95% CI 0.05−0.13 nM) in the respective bio-assays, Cumyl-
PEGACLONE was the most potent SCRA of all the compounds tested in a previous study, 
encompassing over 20 representatives of different SCRA classes 7.  
In response to the emergence of Cumyl-PEGACLONE, it was included in 2018 in the annex of 
the German narcotics law (BtMG), again incentivizing sellers to quickly look for replacement 
analogues. The result was that 5F-Cumyl-PEGACLONE (2,5-Dihydro-2-(1-methyl-1-
phenylethyl)-5-(5-fluoropentyl)-1H-pyrido[4,3-b]indol-1-one) entered the recreational drug 
market as a new non-scheduled SCRA (Figure 1). Following the identification of this compound 
in November 2017, the EU Early Warning System of the EMCDDA sent out a formal notification 
for this compound late 2017. Not surprisingly, identification and case reports for both Cumyl-
PEGACLONE and 5F-Cumyl-PEGACLONE have emerged since then 6,8–12. Initially, SCRAs 
containing a γ-carbolinone core structure were hypothesized to be relatively safe, as no 
lethalities were observed in cases with (over)consumption of Cumyl-PEGACLONE. However, 
several fatalities have been reported during the last few years 13. Also for 5F-Cumyl-
PEGACLONE several fatalities have been reported 10,13. Hence, the relative ‘safety’ of γ-
carbolinones can be questioned 6,10,13. As it is known that fluorination can have a beneficial 
effect on a compound’s activity, resulting in a higher potency, it could be hypothesized that this 
would lead to a higher toxicity of 5F-Cumyl-PEGACLONE 7,14,15. However, no activity data are 
available to confirm this hypothesis. 
In the context of this report, two new Cumyl-PEGACLONE isomers (ethylbenzyl and n-
propylphenyl) were synthesized. These compounds differ in their regulatory status in 
Singapore: whereas Cumyl-PEGACLONE and 5F-Cumyl-PEGACLONE, as well as their 
phenylpropyl isomers, are listed as scheduled substances, this is not the case for their 
ethylbenzyl isomers 16. Neither of these isomeric analogues has been identified in drug 
seizures or patient samples (yet), nor is anything known about (a potential difference in) these 
isomers’ pharmacological/toxicological profile. 
As the toxicological profile of a compound is at least partially linked to its intrinsic receptor 
activation potential, Cumyl-PEGACLONE and its fluorinated variant, as well as the two above-
mentioned isomers, were explored in this study. The activity at the CB1 receptor was appraised 
using two different in vitro receptor-proximal bio-assays, assessing the recruitment of either β-
arrestin2 (β-arr2) or a modified G protein (mini-Gαi) to the activated receptor. The use of two 
recruitment bio-assays also allowed the assessment of possible biased agonism at CB1 of 
these synthetic drugs 7,17. This might be relevant, as some SCRAs may display a certain 
preference, which might have biological and/or toxicological implications. More specifically, we 
previously observed that Cumyl-PEGACLONE did not exhibit biased agonism, while EG-018, 
which has another 3-ring core structure (carbazole instead of γ-carbolinone) showed a 10-fold 
preference towards G protein over β-arr2 recruitment (Figure 1) 7. Overall, these functional 
assays allow us to gain better insight into the (possibly) structurally related ‘functional’ activity 
of these compounds. As most CB1-agonists still provoke psychotropic effects, their broad 
therapeutic utility remains limited. While the research on biased agonism amongst SCRAs is 
still in its infancy, outcomes on signaling pathway-selective agonists could aid the development 
of therapeutics diminishing on-target adverse effects. 
  
MATERIALS & METHODS 
Materials and reagents 
Dulbecco’s modified eagle’s medium (DMEM, GlutaMAX™), Opti-MEM® I Reduced Serum 
Medium, penicillin/streptomycin (10.000 IU/ml and 10.000μg/ml), amphotericin B (250μg/ml), 
glutamine (200mM) and trypsin-EDTA (0.05%) were purchased from Thermo Fisher Scientific 
(Pittsburg, PA, USA). Fetal bovine serum (FBS) was from Biochrom AG (Berlin, Germany).  
The Nano-Glo Live Cell reagent was procured from Promega (Madison, WI, USA). Cumyl-
PEGACLONE (2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-pentyl-1H-pyrido[4,3-b]indol-1-one) 
(purity >99%), Cumyl-PEGACLONE ethylbenzyl isomer (purity >85%), Cumyl-PEGACLONE 
n-propylphenyl isomer (purity >99%) and 5F-Cumyl-PEGACLONE (2,5-Dihydro-2-(1-methyl-
1-phenylethyl)-5-(5-fluoropentyl)-1H-pyrido[4,3-b]indol-1-one) (purity >99%) were synthesized 
(information below) by Chiron AS (Trondheim, Norway). Despite several attempts, the grade 
of purity of the reference standard for the ethylbenzyl isomer was only >85%, owing to technical 
difficulties in the purification. However, throughout this article we handled it in the same way 
as the n-propylphenyl isomer, meaning that the potency values for the ethylbenzyl isomer are 
likely a slight underestimation due to the presence of an impurity. JWH-018 (naphthyl(1-pentyl-
1H-indol-3-yl)methanone) was obtained from LGC (Wesel, Germany). Poly-D-lysine was 
supplied by Sigma Aldrich (Steinheim, Germany) and absolute methanol from Biosolve B.V. 
(Valkenswaard, The Netherlands). The white 96-well plates were obtained from Greiner Bio-
One (Kremsmünster, Austria).  
Synthesis of Cumyl-PEGACLONE & variants 
Details on the chemicals used for the synthesis are provided in Supplementary Data. 
1. Synthesis of 1-substituted 1H-indole-2-methyl-3-carboxylic acids (Figure 2)18 
Sodium hydride (60% in mineral oil, 2.29 g, 57.17 mmol) was added to a solution of 2-
methylindole (5.00 g, 38.12 mmol) in anhydrous DMF (30 mL) at 0 °C and the resulting mixture 
was stirred at this temperature for 20 min, before 1-bromoalkane (41.93 mmol, 1.1 eq.) was 
added. The mixture was stirred at 55 °C for 2 h, before being re-cooled to 0 °C and 
trifluoroacetic anhydride (13.25 mL, 95.29 mmol) was added. The mixture was stirred at 55 °C 
for 2 h and then poured into vigorously stirred ice-water (500 mL), washing once with DMF (5 
mL). The red precipitate was collected by filtration and dried under high vacuum. This 
precipitate was dissolved in methanol (75 mL) and solid KOH (7.49 g, 133.40 mmol) was 
added. This mixture was heated to reflux for 16 h, before being cooled to room temperature 
and concentrated in vacuo. 2 M Hydrochloric acid (50 mL) and ethyl acetate (50 mL) were 
added and the aqueous phase was extracted with ethyl acetate (3 × 50 mL). The combined 
organic extracts were dried over MgSO4, filtered and concentrated. The residue was re-
crystallised from iPrOH to provide acid 1 (5.56 g, 22.68 mmol) as a pale brown crystalline solid. 
2. Amidation of 1-substituted 1H-indole-2-methyl-3-carboxylic acids (Figure 2) 
The appropriate amine (R2NH2, 1.2 eq.) was added to a stirred solution of acid 1 (1.0 eq.), 
EDC hydrochloride (1.5 eq.), 1-hydroxybenzotriazole hydrate (1.5 eq.) and N,N-
diisopropylethylamine (4.0 eq.) in DMF (25 mL). The solution was heated to 55 °C and stirred 
at this temperature for 16 h. The reaction mixture was diluted with ethyl acetate (75 mL) and 
water (75 mL), the layers were separated and the aqueous layer was further extracted with 
ethyl acetate (2 × 75 mL). The combined organic extracts were washed with water (75 mL), 
5% aq. citric acid solution (2 × 75 mL), saturated aqueous NaHCO3 solution (2 × 75 mL) and 
brine (2 × 75 mL), before being dried over MgSO4, filtered and concentrated. Flash column 
chromatography (SiO2, 15% ethyl acetate-petrol) provided the amide 2 as an oil. 
 
3. Synthesis of Cumyl-PEGACLONE derivatives (Figure 2)19 
n-Butyllithium (2.3 M in hexane, 3.0 eq.) was added dropwise to a stirred solution of amide 2 
(1.0 eq.) in anhydrous THF (20 mL) at −30 °C and the stirred solution was allowed to warm 
naturally to 0 °C over 45 min. The solution was re-cooled to −30 °C and anhydrous DMF (4.0 
eq.) was added dropwise. The resulting solution was stirred at −30 °C for 15 min and then at 
room temperature for 90 min. 2 M Hydrochloric acid (degassed by bubbling Argon with stirring 
for 20 mins, 15 mL) was added and the mixture was stirred vigorously at 55 °C for 16 h. The 
mixture was cooled to room temperature, diluted with CH2Cl2 and the pH of the aqueous phase 
was adjusted to pH 10 with 2 M NaOH solution. The aqueous phase was extracted with CH2Cl2 
(3 × 20 mL) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated. Flash column chromatography (SiO2, 15% ethyl acetate-petrol) provided a 
yellow oil which was further purified, if necessary, by preparative HPLC to provide the 
corresponding Cumyl-PEGACLONE derivative. Details about the characterization of the end 
products are provided in Supplementary Data. 
Cell culture 
The in vitro cannabinoid activity of all compounds was assessed by two previously reported 
live cell-based CB1 reporter assays, based on the NanoLuc Binary Technology (Promega) 7,20. 
Different cell lines of human embryonic kidney (HEK) 293T cells, stably transduced with one 
of two cannabinoid reporter systems (CB1 with β-arr2 or CB1 with mini-Gαi protein), were 
routinely maintained at 37°C, 5% CO2, under humidified atmosphere (passaged at confluence 
of 80-90%). They were cultured in DMEM (containing high glucose levels) supplemented with 
10% heat-inactivated FBS, 100 IU/ml of penicillin, 100 μg/ml of streptomycin and 0.25 μg/ml 
of amphotericin B. For the assays, the cells were seeded on a poly-D-lysine coated 96-well 
plate at a concentration of 5x104 cells/well and incubated overnight. The next day, the cells 
were washed twice with 150 μL Opti-MEM I Reduced Serum Medium to remove any remaining 
proteins (present in FBS) and 100 μL Opti-MEM I Reduced Serum Medium was added to each 
well. Subsequently, the Nano-Glo Live Cell reagent (Promega) was prepared by diluting the 
Nano-Glo Live Cell substrate 1 to 20 with Nano-Glo LCS Dilution buffer. Following addition of 
25 μL of this nonlytic detection reagent to each well, the plate was read during equilibration of 
the signal (10-15 min) in the TriStar² LB 942 Multimode Microplate Reader (Berthold 
Technologies GmbH & Co., Germany). After this equilibration period, 10 μL of the freshly 
prepared 13.5× stock solutions (50% methanol in Opti-MEM I Reduced Serum medium) of the 
agonists was added in order to reach the reported in-well-concentrations and luminescence 
was continuously monitored for 120 min. Solvent controls were taken along to control for the 
amount of methanol present in the stock solutions. No problematic effect on the cells was 
observed for the present concentration of methanol in the wells (3.7%), probably given the 
short readout time of the assay 14. In addition to the panel of Cumyl-PEGACLONE variants and 
solvent controls, JWH-018 was tested in each individual experiment as reference compound. 
Data analysis & Statistical Analysis.  
As FACS-sorted (Fluorescence-Activated Cell Sorting) stably transduced cells were used, 
there inherently is less variability in these assays. Hence, data were obtained in minimally three 
independent experiments, each performed in duplicate. Following the equilibration period, a 
baseline-correction was made of the absolute signals to correct for the inter-well variability. 
The final corrected luminescence measurements were obtained by subsequently subtracting 
the signals of the vehicle control samples from those of the experimental samples. These 
corrected signals were used to calculate the area under the curve (AUC) as measure for 
cannabinoid activity. All data were evaluated with the Grubbs test to detect outliers, before 
further statistical analysis. 
Curve fitting and statistical analysis were performed using GraphPad Prism software (San 
Diego, CA, USA). The results are represented as normalized mean area under the curve (AUC) 
± standard error of mean (SEM). EC50 values as measure of potency and Emax values as 
measure of efficacy were determined for all compounds by sigmoidal curve fitting the 
concentration−effect curves via nonlinear regression. A three parametric logistic fit was used 
for all compounds to comply to the prerequisite for calculating the bias factor in further data 
analysis (hill slope equals 1). The activity of the different SCRAs was evaluated in comparison 
with the reference compound JWH-018. The resulting cannabinoid activity is represented as 
the percentage (%) CB1 activation of a compound relative to the maximum receptor activation 
(Emax) of JWH-018. 
Bias calculation & Statistical analysis 
For the evaluation and quantification of biased agonism, we used the relative activity-based 
method by calculating the bias factor using eq1 as previously described 21. 






)      (eq1) 
This bias factor calculation entails the logarithm of the ratio of the intrinsic relative activity (RAi) 
value of a compound for recruitment of β-arr2 to the value for recruiting mini-Gαi. Therefore, 
the intrinsic relative activity (RAi) was calculated for each compound of the tested panel for 
their response in both bioassays using eq2. Herein, Emax,i and EC50,i represent the efficacy and 
potency, respectively, of the tested Cumyl-PEGACLONE variants. Emax,JWH-018 and EC50,JWH-018 
represent the efficacy and potency for the reference compound JWH-018, which, as in previous 
work, is considered unbiased 7. 
𝑅𝐴𝑖 =  
𝐸𝑚𝑎𝑥,𝑖 × 𝐸𝐶50,𝐽𝑊𝐻−018
𝐸𝐶50,𝑖 × 𝐸𝑚𝑎𝑥,𝐽𝑊𝐻−018
     (eq2) 
Statistical analysis was performed using GraphPad Prism software (San Diego, CA, USA) to 
detect statistical differences in the calculated bias factors of all compounds in comparison to 
the non-biased reference compound JWH-018. Statistical significance (P < 0.05) was 
determined using a non-parametric (Kruskal-Wallis) one-way ANOVA test, followed by post 
hoc analysis using Dunn’s multiple comparison test.  
 
RESULTS 
In vitro CB1 receptor activity 
For the in vitro evaluation of the intrinsic receptor activation potential, all γ-carbolinones were 
compared to the reference SCRA, JWH-018. All Cumyl-PEGACLONE variants were able to 
activate the CB1 receptor in the two separate bio-assays, measuring β-arr2 or mini-Gαi 
recruitment (Figure 3 & Supplementary Figure 1). EC50 and Emax values were derived as 
measures of potency and relative efficacy, respectively (Table 1).  
Both in terms of potency and relative efficacy, Cumyl-PEGACLONE and 5F-Cumyl-
PEGACLONE were found to be much more active compared to JWH-018 in both CB1 activation 
bio-assays. The data obtained for Cumyl-PEGACLONE (β-arr2: EC50 = 0.23 nM and Emax = 
344%; mini-Gαi: EC50 = 0.17 nM and Emax = 194%) are in line with what we previously observed 
7. 5F-Cumyl-PEGACLONE hadn’t been tested in these settings before and gave similar activity 
profiles compared to the non-fluorinated parent compound, for both the recruitment of β-arr2 
(EC50 = 0.58 nM and Emax = 356%) and mini-Gαi (EC50 = 0.22 nM and Emax = 174%). Hence, 
while in addition to Cumyl-PEGACLONE, also 5F-Cumyl-PEGACLONE now ranks amongst 
the most potent SCRAs evaluated by these in vitro bioassays so far, no beneficial effect of 
fluorination could be observed in terms of intrinsic CB1 receptor activation potential. Efficacy-
wise, both compounds also classify as highly efficacious SCRAs, although even higher efficacy 
values have been measured in previous studies (e.g. for AB-CHMINACA in the β-arr2 assay) 
22–24. 
Interestingly, a very divergent activity profile was observed for both isomeric variants of Cumyl-
PEGACLONE (ethylbenzyl isomer and n-propylphenyl isomer). The concentration-response 
curves were clearly shifted to the right, resulting in higher EC50 and lower Emax values (EC50 = 
123-170 nM and Emax = 25.8-38.0%). The very high activity of Cumyl-PEGACLONE, therefore, 
seems to (at least partially) rely on an adequate linker. The relatively low activity of the isomers 
was observed in both CB1 activation bio-assays. No difference in EC50 and Emax values was 
observed for the two isomers, although one should be aware that the reference standard for 
the ethylbenzyl isomer was only >85% pure (as discussed in Materials & Methods). 
 
Biased agonism at the CB1 receptor 
As all compounds were tested in the two different bio-assays, this also allowed the assessment 
of possible biased agonism by calculating the compounds’ bias factor β (Table 1). Although 
the relative activity-based approach, taking into account both potency and efficacy, did not 
reveal a significant bias of any of the tested SCRAs, compared to the non-biased JWH-018, 
both isomers did cluster together, with a trend differing from (5F-)Cumyl-PEGACLONE (Figure 
3 & Supplementary Figure 2). Given this apparent different trend, statistical significance was 
analyzed for a difference in biased agonism between the isomers and Cumyl-PEGACLONE 
itself, but no statistically significant bias was detected. 
 
DISCUSSION 
The synthesis of structurally very diverse SCRAs seems to be driven by the will to circumvent 
structure-based legislation via scaffold hopping, isomer exploration and so on. When first 
characterizing the new SCRA Cumyl-PEGACLONE in 2017, structural similarities were 
observed with Cumyl-PICA (Figure 1) 5. Hereby, Cumyl-PEGACLONE exhibits scaffold-
hopping to a new tricyclic γ-carbolinone core structure. We and others have already reported 
Cumyl-PEGACLONE as a very potent and full agonist of the CB1 receptor. In general, higher 
binding affinity and lower EC50 values have been reported than those for Cumyl-PICA, albeit 
in different experimental settings, which hampers easy comparison of EC50 values 5,7,25. 
Regardless of the differences in assay set-ups, the scaffold hopping to a γ-carbolinone core 
can be considered successful in terms of creating a SCRA with ultrahigh activation potential 
of the CB1 receptor. It can thus be hypothesized that the use of Cumyl-PEGACLONE could 
therefore entail a greater risk of overdosing and inducing severe adverse effects.  
On the contrary, the activity-profiling of Cumyl-PEGACLONE ethylbenzyl and n-propylphenyl 
isomers revealed that structural isomer exploration of Cumyl-PEGACLONE did not yield 
analogues with similar or higher activity but, instead, led to compounds with a strongly reduced 
intrinsic receptor activation potential. Based on insights obtained from molecular docking of 
Cumyl-PEGACLONE in the cryo-EM structure of the CB1-Gαi complex, possible steric 
hindrance can be hypothesized at the orthosteric CB1 binding site 7. The presence of a more 
bulky substituent on the linker or an increased linker length could hamper a hydrogen bonding 
network with S3837.39 and water molecules in the pocket, possibly explaining the observed 
lower CB1 activation potential. 
Initially, 5F-Cumyl-PEGACLONE was thought to be associated with a higher toxicity than 
Cumyl-PEGACLONE, although also several fatalities, involving mono-intoxications, have been 
observed with the latter 13. At this point, it is thus unclear whether there actually is a difference 
in toxicity in vivo. Interestingly, fluorination of Cumyl-PEGACLONE did not provide the 
postulated beneficial effect on the intrinsic cannabinoid activity. Both the potency and efficacy 
of the parent compound and the 5-fluorinated analogue were similar regarding recruitment of 
both β-arr2 and mini-Gαi. Hence, these compounds demonstrate similar intrinsic CB1 receptor 
activation potential. This finding is not in line with other reports where the fluorinated SCRA 
usually exerts a higher potency than the unfluorinated analog 15,26. Possibly there is a limit at 
the potency that can be reached by this type of SCRAs, and potentially Cumyl-PEGACLONE 
(and hence also its 5F analog) has reached that limit. 
Earlier, the presumed relatively low toxicity of Cumyl-PEGACLONE was postulated to originate 
from a more homogenous distribution and low concentrations of the compound in products that 
were sold, as this SCRA initially appeared in herbal blends and e-liquids only 6. However, even 
when the pure substance became available in July 2017 as a research chemical, there 
apparently wasn’t an increase in severe or lethal intoxication cases. So, at the time, the most 
plausible explanation for the lack of severe intoxication or death cases with Cumyl-
PEGACLONE remained an intrinsic relatively low toxicity of the compound, when compared to 
other SCRAs on the recreational drug market. In line with this low toxicity hypothesis, a group 
of related carboline derivatives was described as a possible medical treatment for respiratory 
and non-respiratory diseases in a US patent of Leftheris et al. 27. In addition, Cheng et al. 
suggested a group of γ-carbolines as a class of SCRAs combining water solubility and low 
CNS penetration, which could explain both medical potential and (previously postulated) low 
(central) toxicity 28. However, contrasting with these reports are a number of fatalities reported 
in Australia, in which even sub-ng/ml concentrations of Cumyl-PEGACLONE in blood were 
considered as highly probable to have contributed to death 13. Similarly, for 5F-Cumyl-
PEGACLONE, low blood concentrations have been linked to fatalities 10,13.  Hence, whether 
there is a difference in toxicity between Cumyl-PEGACLONE and 5F-Cumyl-PEGACLONE is 
currently not clear. For cathinones, another class of NPS, it has been suggested that 
fluorination can increase the compound’s ability to cross the Blood-Brain-Barrier (BBB) 
(Fabregat-Safont et al., submitted). In a similar scenario, higher 5F-Cumyl-PEGACLONE 
concentrations might be reached at the target sites in the brain - only in vivo experiments can 
provide a definitive answer to this. Furthermore, besides a compound’s intrinsic receptor 
activation potential and BBB penetrability, additional factors will determine the eventual toxicity 
of a compound in vivo. Amongst these are potential differential off-target effects, differences 
in resorption, metabolic stability, or the existence of active metabolites that may contribute to 
the overall in vivo cannabinoid activity. Differences in metabolites between Cumyl-
PEGACLONE and the 5-fluorinated analogue have been identified, but no information on their 
activity is available yet 29. Neither has the in vivo metabolic stability of these γ-carbolinones 
been reported so far. Only consideration of all contributing factors in combination with further 
in vivo examinations can provide an adequate comparison of both compound’s toxicological 
profile.  
Reported concentrations of Cumyl-PEGACLONE ranged from 0.38 nM to 34.9 nM (0.14 to 13 
ng/ml) in serum from clinical samples and from 0.32 nM to 24.2 nM (0.12 to 9 ng/ml) in femoral 
post mortem blood samples 6,13. Cases of 5F-Cumyl-PEGACLONE included a concentration 
range of 0.24 nM – 1.2 nM (0.09 to 0.45 ng/ml) 10,13. The latter concentrations, derived from 
post mortem samples, should be interpreted with caution for different reasons, amongst which 
post mortem redistribution and non-availability of the exact methods that were applied for 
quantification. Thus, for both compounds, observed in vivo concentrations correspond to in 
vitro concentrations around or above the EC50, representing a pronounced CB1 activation, 
certainly taking into account the high efficacy of these compounds.  
As to biased agonism, no statistical difference in preference towards recruitment of either β-
arr2 or mini-Gαi was detected in comparison to the non-biased reference compound JWH-018. 
Keeping in mind that varying levels of signal amplification across assays can confound the 
interpretation of biased agonism, especially in the case of low-efficacy agonists like the 
evaluated isomers in this study, it is important to note that no signal amplification (like in for 
example cAMP assays) occurs in the bio-assays applied here, which were designed to 
maximally ensure an equally effective engagement of both signaling molecules. It is relevant 
to mention that in vivo active metabolites could exert divergent activity profiles from the parent 
compound. Accordingly, these can possibly contribute to overall or delayed in vivo biased 
agonism, which was not studied here 30. 
 
CONCLUSION 
Both Cumyl-PEGACLONE and 5F-Cumyl-PEGACLONE intoxications have been linked to 
fatalities. Currently, the relatively limited number of cases does not allow to judge whether the 
fluorinated derivative is more toxic than Cumyl-PEGACLONE, which was originally thought to 
be relatively safe. This study clearly demonstrates that both compounds do not differ in in vitro 
intrinsic CB1 receptor activation potential. Whether these compounds differ in BBB permeability 
or whether improved metabolic stability or active metabolites play a role in intoxications was 
not evaluated here, but could be the topic of future work. Furthermore, Cumyl-PEGACLONE 
ethylbenzyl and n-propylphenyl isomers were found to have a strongly reduced CB1 receptor 
activation potential, both in terms of potency and efficacy, notwithstanding a potential 
underestimation for the ethylbenzyl isomer due to the lower (>85%) purity level. Finally, no 
statistically significant biased agonism was observed in this in vitro study for any of the 
evaluated γ-carbolinones. In conclusion, Cumyl-PEGACLONE and 5F-Cumyl-PEGACLONE 
rank amongst the most potent SCRAs tested in these assays. Their strong activity is seemingly 
highly dependent on an adequate linker. In the future, evaluation of other newly emerging γ-
carbolinones analogs with varying substitutions (e.g. Cumyl-CH-MEGACLONE with varying 
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TABLE 1. Overview of Potency (EC50), Efficacy (Emax, relative to JWH-018) and bias factor (β) for the SCRAsa 
 




Figure 1: Structures of all compounds: the ones evaluated in this study are displayed in black 
(Cumyl variants), the ones mentioned but not studied in this paper (EG-018, Cumyl-PICA) or 
used as reference (JWH-018) are displayed in light grey. 
Compound 
β-arrestin2  mini- Gαi 
β ± SEM 
EC50 (nM) Emax (%)  EC50 (nM) Emax (%) 
JWH-018 14.4 
(7.76 – 27.8) 
101 










(314 – 375) 
 
0.17 
(0.10 – 0.30) 
194 
(180 – 209) 
0.04 ± 0.15 
5F-Cumyl-PEGACLONE 0.58 
(0.32 – 1.00) 
356 
(323 – 389) 
 
0.22 
(0.15 – 0.33) 
174 
(165 – 184) 









(43.5 – 329) 
36.3 
(30.2 – 42.6) 




(87.1 – 321) 
27.1 
(24.3 – 30.0) 
 
123 
(44.3 - 340) 
38.0 
(32.1 – 44.2) 
0.26 ± 0.21 
 
 
Figure 2: Chemical synthesis of Cumyl-PEGACLONE and variants. 1) Synthesis of 1-
substituted 1H-indole-2-methyl-3-carxylic acids; 2) Amidation of 1-substituted 1H-indole-2-





Figure 3: Graphical representation of the concentration-response curves, reflecting the activity 
of all compounds in the CB1 bio-assays measuring recruitment of β-arrestin2 (left panel) or 
mini-Gαi (right panel). AUC: Area Under the Curve (normalized to the maximal receptor 
activation of JWH-018). 
 
 
Supplementary Figure 1: CB1 activation profiles of all tested compounds from one 
representative experiment in the β-arr2 assay. Note the difference in scale in the zoomed-in 
graphs of the isomers. 
 
 
Supplementary Figure 2: Concentration-response curves in both the CB1 bio-assay measuring 
recruitment of β-arrestin2 and the bio-assay measuring mini-Gαi recruitment, graphically 
represented per individual compound. Note the difference in scale between the upper and 
lower panels. AUC: Area Under the Curve (normalized to the maximal receptor activation of 
JWH-018). 
 
 
